Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss

Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss

August 18, 2026Posted inBiotechnology

Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and concern,” Kolon TissueGene is laying off 37 employees at its Maryland headquarters.

Post navigation

Previous Post
Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes
Next Post
TUM develops single-photon sources to advance quantum communication tum-develops-single-photon-sources-to-advance-quantum-communication

Recent Posts

  • UTIA Hosts Southern Weed Science Society Weed Contest
  • University Hospitals, Case Western Fund Six Teams Through 2026 Collaborative Science Awards
  • Deeper crop-residue burial may protect maize from ear rot and mycotoxins
  • Workshop Advances Pediatric Therapeutic Development for Osteosarcoma
  • Zebrafish Toxicology Needs Clearer Links to Real-World Environmental Risks

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top